D. Boral Capital lowered the firm’s price target on Biomea Fusion (BMEA) to $16 from $128 and keeps a Buy rating on the shares. The company announced a shift to focus on metabolic disease and ...
REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback